Form 4: Nurix Therapeutics Director Edward C. Saltzman Acquires 25,000 Stock Options
SEC Form 4 Filing
Director Edward C. Saltzman acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025.
Summary
- On May 19, 2025, Edward C. Saltzman, a director of Nurix Therapeutics, Inc., acquired 25,000 stock options.
- The exercise price of these options is $9.51.
- The options vest fully on the earlier of the next annual meeting of the Issuer's stockholders or May 19, 2026, contingent upon continued service to the Issuer.
- The expiration date for these options is May 18, 2035.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, regarding the company's securities. This allows investors to monitor the actions of those with the most knowledge of the company's prospects.
Stakeholder Impact
- The acquisition of stock options by a director aligns their interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of transaction: Director Stock Option (right to buy) acquired |
| 05/19/2025 | Date of report |
| 05/19/2026 | Vesting date of stock options, contingent upon continued service |
| 05/18/2035 | Expiration date of stock options |
Keywords
stock options, Form 4, Nurix Therapeutics, NRIX, director, beneficial ownership, Edward C. Saltzman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.